Brigham researchers use AI tools to uncover connections between radiotherapy for lung cancer and heart complications

Researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, have used artificial intelligence tools to accelerate the understanding of the risk of specific cardiac arrhythmias when various parts of the heart are exposed to different thresholds of radiation as part of a treatment plan for lung cancer. Their results are published in JACC: CardioOncology.

“Radiation exposure to the heart during lung cancer treatment can have very serious and immediate effects on a patient’s cardiovascular health,” said corresponding author Raymond Mak, MD, of the Department of Radiation Oncology at Brigham and Women’s Hospital. “We are hoping to inform not only oncologists and cardiologists, but also patients receiving radiation treatment, about the risks to the heart when treating lung cancer tumors with radiation.”

The emergence of artificial intelligence tools in health care has been groundbreaking and has the potential to positively reshape the continuum of care, including informing treatment plans for patients with cancer. Mass General Brigham, as one of the nation’s top integrated academic health systems and largest innovation enterprises, is leading the way in conducting rigorous research on new and emerging technologies to inform the responsible incorporation of AI into care delivery. 

For patients receiving radiation therapy to treat non-small cell lung cancer (NSCLC), arrhythmias or irregular rhythms of the heart can be common. Because of the close proximity of the heart to the lungs and with NSCLC tumors being near or around the heart, the heart can receive collateral damage from radiation dose spillage meant to target the cancer tumors. Prior studies have found that this type of exposure to the heart is associated with general cardiac issues. However, this nuanced study demonstrated that the risk for different types of arrhythmias can vary significantly based on the pathophysiology and cardiac structures that are exposed to different levels of radiation.

In order to classify the types of arrhythmias that are associated with cardiac substructures receiving radiation, researchers conducted a retrospective analysis on 748 patients in Massachusetts, who were treated with radiation for locally advanced NSCLC. The arrhythmia subtypes cataloged included atrial fibrillation, atrial flutter, other supraventricular tachycardia, bradyarrhythmia, and ventricular tachyarrhythmia or asystole.

The team’s statistical analyses indicated that about one out of every six patients experienced at least one grade 3 arrhythmia with a median time of 2.0 years until the first arrhythmia. Grade 3 classifications are considered serious events that likely need intervention or require hospitalization. They also found that almost one-third of patients who experienced arrhythmias also suffered from major adverse cardiac events.

The arrhythmia classes outlined in the study did not entirely encompass the range of heart rhythm issues that are possible, but the authors note that these observations still create a better understanding of the possible pathophysiology pathways and potential avenues for minimizing cardiac toxicity after receiving radiation treatment. Their work also offers a predictive model for dose exposure and the type of expected arrhythmia.

For the future, the researchers believe that radiation oncologists should collaborate with cardiology experts to better understand the mechanisms of heart injuries and their connection to radiation treatment. In addition, they should take advantage of modern radiation treatment to actively sculpt radiation exposure away from the specific cardiac regions that are at high risk for causing arrhythmias. According to Mak, this study, alongside previous research, will help with surveillance, screening, and informing radiation oncologists on which parts of the heart to limit radiation exposure to, and in turn, mitigate complications.

“An interesting part of what we did was leverage artificial intelligence algorithms to segment structures like the pulmonary vein and parts of the conduction system to measure the radiation dose exposure in over 700 patients. This saved us many months of manual work,” said Mak. “So, not only does this work have potential clinical impact, but it also opens the door for using AI in radiation oncology research to streamline discovery and create larger datasets.”

Authorship: In addition to Mak, BWH authors include Christopher Kehayias, Christian Guthier, John He, Mina Bakhtiar, David E. Kozono, Paul C. Zei, and Anju Nohria. Other authors include Katelyn M. Atkins, Samuel C. Zhang, Jordan O. Gasho, Katrina D. Silos, and Andriana P. Nikolova.

Disclosures: Dr. Atkins has received honoraria from healthcare publisher, OncLive. Dr. Mak is a consultant for AstraZeneca, ViewRay, Novartis, Sio Capital Management, and Varian Medical Systems. He is also an advisory board member for and has received research grant funding (unrelated to the current work) from ViewRay and AstraZeneca. Dr. Nohria has received consulting fees from Altathera Pharmaceuticals, AstraZeneca, Bantam Pharmaceuticals, Regeneron Pharmaceuticals, and Takeda Oncology, and research grant funding from Bristol Myers Squibb. All other authors reported that they have no relationships relevant to the contents of the paper.

Paper cited: Atkins, K et al. “Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy” JACC: CardioOncology. DOI: 10.1016/j.jaccao.2024.07.005.

###

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.